Personalis slips after Tempus AI strikes $1.5 bln takeover deal
PSNL•Personalis falls after Tempus AI takeover deal
- Shares of cancer diagnostics firm Personalis
PSNL.Ofall 5.9% to $14.49 premarket - Tempus AI
TEM.Ois acquiring Personalis in a deal valued at $1.5 billion - Personalis shareholders will receive $16.25/share, a 5.6% premium to the last closing price of $15.39
- Tempus will gain access to Personalis' NeXT Personal cancer test, which helps detect tiny amounts of tumor DNA to monitor treatment response and identify cancer recurrence early
- The deal is expected to close in late 2026 or early 2027
- Tempus AI shares are down 4.4% at $50.18 before the bell
- As of last close, PSNL is up 93.3% and TEM is down 11% YTD
